Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Capital Expenditures
Avadel Pharmaceuticals PLC
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Capital Expenditures
-$15.2m
|
CAGR 3-Years
-177%
|
CAGR 5-Years
-241%
|
CAGR 10-Years
-27%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Capital Expenditures
-$93.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
6%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Capital Expenditures
-$209.8m
|
CAGR 3-Years
25%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-19%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Capital Expenditures
-$121k
|
CAGR 3-Years
-20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Capital Expenditures
-€5.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-8%
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Capital Expenditures
€0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Capital Expenditures?
Capital Expenditures
-15.2m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Capital Expenditures amounts to -15.2m USD.
What is Avadel Pharmaceuticals PLC's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-27%
The average annual Capital Expenditures growth rates for Avadel Pharmaceuticals PLC have been -177% over the past three years , -241% over the past five years , and -27% over the past ten years .
